T akotsubo cardiomyopathy (TCMP), also known as stress cardiomyopathy or broken-heart syndrome, is an increasingly recognized form of transient left ventricular (LV) dysfunction that is often completely reversible. [1] [2] [3] [4] It is diagnosed in 1% to 2% of patients initially presenting with symptoms suggestive of acute coronary syndrome. 2 It often presents with dyspnea, hypotension, syncope, elevated troponin levels, and ST elevations or T wave inversions on electrocardiography.
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Several variants of TCMP have been described. The typical or apical variant consists of a hyperkinetic LV base with focal apical akinesis resulting in apical ballooning and reduced ejection fraction. Other variants such as the inverted or basal pattern (circumferential basal hypokinesis and apical hypercontractility), the mid LV variant (circumferential midventricular hypokinesis and both basal and apical hypercontractility), and the biventricular apical and right ventricular pattern have been described. 1, 4 The exact pathogenesis is not fully understood with vast unanswered questions remaining, though a central role of catecholamines has been widely accepted. The stress related to metabolic dysfunction can be the initial trigger for the sympathetic surge found in this disorder. Several case reports have described its occurrence secondary to a number of endocrine disorders, though this has not been comprehensively evaluated. Here we have attempted to review all of the published reports of associations of endocrine conditions with TCMP and discuss some postulated mechanisms by which this may occur. This review will mainly focus on the potential association of pituitary, thyroid, adrenal, and estrogen metabolic disorders with this transient reversible cardiomyopathy and how hormones can impact cardiac function. This review suggests that hormonal dysregulation should be considered in patients presenting with cardiac abnormalities.
Pathophysiology of TCMP
The pathophysiology of TCMP is complex and numerous mechanisms have been postulated, including hypothalamicpituitary-adrenal axis-mediated sudden sympathetic activation and surge in concentrations of circulating catecholamines, neuroendocrine circuit, multivessel coronary vasospasm, coronary thrombus, and plaque rupture in the left anterior descending artery wrapped around the apex with rapid autolysis of the clot. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Reversible perfusion defects, sympathetically mediated microvascular dysfunction, and coronary vasospasm have been documented in patients with TCMP. [16] [17] [18] However, these observational findings were not supported in a rat model of takotsubo-like cardiac dysfunction. 16 Nevertheless, catecholamine-driven cardiac dysfunction remains the predominant hypothesis ( Figure 1 ). The pathophysiology can be broadly divided in 2 phases. The first phase starts with cognitive centers of the brain with a special role of the hypothalamic-pituitary-adrenal axis resulting in appropriate catecholamine release in response to stress. At the onset, serum catecholamine and plasma brain natriuretic peptide levels are elevated significantly in TCMP, even higher than the levels found in patients with acute cardiac decompensation secondary to an ischemic event, supporting a role of hypothalamic-pituitary-adrenal gain and a sympathetic-driven pathogenesis. Serum catecholamine levels subsequently decline but remain substantially higher than in those patients with acute myocardial infarction after 1 week of onset. In contrast, plasma brain natriuretic peptide levels decline rapidly in TCMP compared with acute myocardial infarction correlating with rapidly improving LV systolic function.
The second phase is the cardiac response to released catecholamines. Transient myocardial stunning often results from direct cardiomyocyte toxicity via increased calcium, microvascular dysfunction or vascular spasm, and ischemia secondary to excess catecholamines. [5] [6] [7] Increased sympathetic and adrenomedullary outflow can also cause increased LV afterload leading to outflow tract obstruction, catecholamine myocarditis, and changes in b-adrenergic receptor signaling. 8 Oxidative stress often exaggerates myocardial stunning by affecting calcium homeostasis and causing excitation-contractive uncoupling resulting in myocardial dysfunction. [6] [7] [8] The histopathology of the myocardium in this condition differs from that found in ischemic insults and includes a neutrophil-predominant inflammation, contraction band necrosis, and fibrosis. 9 These changes probably reflect calcium cardiotoxicity rather than ischemic necrosis. The pattern of ventricular wall abnormality in TCMP also points towards a neurally mediated mechanism of cardiac injury. [11] [12] [13] Certain variants of TCMP can be attributed to involvement of different branches of the cardiac sympathetic system, though it has not been fully mapped yet. 13 In the classical variant, apical ballooning and akinesis are associated with a hyperkinetic basal segment. A number of anatomic and physiologic factors have been thought to make the apical region of the heart more vulnerable to wall abnormality. Anatomically, it is located in a watershed area of major branches of coronaries arteries, making it more susceptible to developing ischemia. Structurally, the apex lacks a 3-layered myocardium and ability to regain elasticity after maximal expansion. Physiologically, there are increased sympathetic terminals in the apex as compared with the base, which makes it more susceptible to sudden catecholamine surges. However, in other atypical forms of TCMP, the apex may actually be hypercontractile. Various theories have been postulated including a migratory form in which apical hypercontractibility may occur as part of the spectrum. 13 Rupture of atherosclerotic plaque does not explain the differential involvement itself, though a reduction in the number of synaptic terminals at the apex after akinesis has been suggested as the apex actually recovers fairly quickly after global dysfunction. [11] [12] [13] [14] [15] Excessive LV afterload has also been studied as an underlying mechanism. [19] [20] [21] Normally, there is uniform distribution of wall stress along the left ventricle (LV). However, if regional wall stress develops quickly, the LV may not have time to adapt and this may result in regional dysfunction. Recently, increased LV end-systolic pressure has been documented in the acute phase. 19 It is postulated that this is exaggerated in elderly women, as on average they have lower mass and LV volume than men and with increasing age adaptation is further limited. 20 Interestingly, LV outflow obstruction is dynamic and may not be routinely observed at the time of echocardiographic examination. A genetic predisposition to TCMP has been suggested. Recurrence of TCMP in 1 person and familial associations point towards a potential role of genetic factors. For example, polymorphisms in adrenergic receptors and FMR 1 gene mutations have been reported. 22, 23 However, expression profiling of cardiac genes in the acute phase of TCMP has not been complete and remains a subject of ongoing research.
Endocrine Dysregulation and Association With TCMP
Pheochromocytoma and TCMP Pheochromocytoma is a rare neuroendocrine tumor that usually originates from the adrenal gland chromaffin cells or extra-adrenal paraganglions, resulting in overproduction of catecholamines. 24 Since the sympathetic system still remains the cornerstone for TCMP pathogenesis with special emphasis on b-adrenergic receptor trafficking in the presence of excess catecholamines, an association of these 2 conditions seems plausible. Many of the diagnostic guidelines exclude pheochromocytoma before diagnosing a patient with TCMP, while others recognize the occurrence of TCMP-like myocardial dysfunction in these patients. 25, 26 Catecholamine-associated cardiac complications are associated with increased morbidity and mortality. 24, 27 At physiological levels, epinephrine is primarily inotropic through b1 and b2 adrenergic receptors. However, at supraphysiological levels, stimulation of b1 receptors produces cardiomyocyte apoptosis and stimulation of b2 receptors results in negative inotropic effects, possibly from a switch in b2 receptor coupling. 27 Myocardial alteration and cardiomyopathy secondary to sympathetic stimulation are often reversible with pharmacological and surgical treatment of the pheochromocytoma. However, recently it has been suggested that subclinical systolic and diastolic dysfunction may persist over time despite cure of the underlying pathology with no biochemical evidence of ongoing catecholamine activity. Agrawal et al reported the prevalence of "idiopathic" pheochromocytoma-related nonischemic cardiomyopathy to be 17% in their overall cohort, and 25% in patients who underwent diagnostic cardiac imaging, findings that are slightly higher than 11% reported previously. 28 33 The diagnosis of pheochromocytoma is often missed on the initial presentation of patients diagnosed with TCMP. 24, 32, 33 It is often later that the diagnosis is made after heightened suspicion of excessive secretion of vasoactive peptides, nonresolving symptoms, and inability to attain hemodynamic stability prompt a search for an alternative cause. Pheochromocytoma is often associated with atypical presenting symptoms, a history of malignant hypertension or unstable hemodynamics on presentation. 32, 33 Furthermore, TCMP precipitated by a pheochromocytoma is associated with higher rates of in-hospital complications such as noncardiogenic pulmonary edema, cardiogenic shock, and heart failure. 32, 33 Recognition of pheochromocytoma is critical, particularly in association with TCMP, as routine administration of a b-blocker could be hazardous in the setting of unopposed hyperactivation of a-adrenergic receptors, further worsening the condition. Therefore, high suspicion is warranted in the clinical setting because both of the processes are catecholamine driven. The underlying factors for catecholamine excess may be multifactorial as well. Screening for pheochromocytoma should always be considered in the diagnostic workup for TCMP, especially in the younger population, when the presentation has atypical features, and when no trigger can be identified.
As mentioned above, paragangliomas are also neuroendocrine tumors associated with catecholamine excess, and hence it is plausible that catecholamine-mediated cardiomyopathy such as TCMP could be observed in this setting as well. Gagnon et al reported an incidence of acute takotsubolike cardiomyopathy of 2.6% in a series of 152 patients with catecholamine-secreting paragangliomas. 34 39 Estrogen receptors are also expressed in cardiac tissue and can play a role in modulating catecholamine effects on the heart. Experiments on rat heart have shown cardioprotective effects of estrogen via blunting of catecholamine-induced tachycardia and reducing ischemia/reperfusion-induced arrhythmias. 39, 40 Ueyama et al demonstrated upregulation of cardioprotective peptides and attenuation of sympathoadrenal outflow after chronic estrogen supplementation in an animal model exposed to immobilization stress. 38, 39 Another study demonstrated reversal of upregulation of b1 receptors and increased cardiac sensitivity in bilateral ovariectomized rats after estrogen supplementation. 40 Kuo et al described a single-center review of TCMP in postmenopausal women, none of whom were taking estrogen replacement therapy. 35 Another study by Komesaroff et al demonstrated attenuated catecholamine and glucocorticoid response to mental stress in perimenopausal women after estrogen supplementation. 43 Estrogen deficiency in the menopausal state can result in exaggerated reactivity to stress via an autonomic surge in the absence of cardioprotective peptides ( Figure 2 ). A role of estrogen supplementation in postmenopausal women to protect against TCMP has been suggested, but human trial data in this regard are scant.
Thyroid Disorders and TCMP
Recently there has been increasing evidence to suggest the occurrence of TCMP in patients with thyroid dysfunction. It has been reported to occur in patients with Graves disease, Hashimoto thyroiditis, toxic multinodular goiter, apathetic hyperthyroidism, thyroid storm, iatrogenic hyperthyroidism, subclinical hyperthyroidism, transient hyperthyroid states, following radioactive iodine treatment, following thyroidectomy, and even in hypothyroid or euthyroid states. However, the mechanism by which different thyroid functional states can trigger TCMP remains unclear. Table 1 summarizes case reports describing TCMP occurring in patients with thyroid disorders. Thyroid hormone effects on the cardiovascular system are well documented and hyperthyroid states can result in increased cardiac output, up to 300% higher than that found in euthyroid individuals. [70] [71] [72] [73] [74] Thyroid hormone increases heart rate and myocardial contractility while simultaneously decreasing systemic vascular resistance, thereby resulting in activation of the renin-angiotensin system. Both genomic and nongenomic actions have been suggested. Triiodothyronine, the active form of thyroid hormone, acts at the nuclear level and increases transcriptional activation of cardiac proteins, both structural and regulatory proteins such as Na + /K + ATPase, sarcoplasmic reticulum Ca 2+ -ATPase, voltage-gated ion channels, myosin heavy chain and b-adrenergic receptors. Nongenomic effects involve membrane ion channels and endothelial nitric oxide synthase, resulting in vascular relaxation and decreased systemic resistance.
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The thyroid and adrenergic systems are closely linked, and hyperthyroid states indeed resemble hyperadrenergic states. It is suggested that thyroid hormones potentiate the actions of normal levels of catecholamines and result in exaggerated inotropic and chronotropic effects ( Figure 2 ). Findings of upregulation of b-adrenergic receptors in the heart support this notion, although this is not always accompanied by simultaneous cardiac sensitivity to catecholamines. 74 Some studies have documented low-to-normal catecholamine levels in hyperthyroid states. 75 Animal studies have shown an intact cardiovascular response to hyperthyroidism even when all 3 b-adrenergic receptors were blocked. 76 This raises the possibility of a mechanism other than an adrenergic-mediated one. Some reports suggest that epicardial arterial spasm may occur, resulting in vasospastic angina, while others have hypothesized a critical imbalance of myocardial oxygen supply and demand exclusive of coronary spasm or coronary artery disease. [77] [78] [79] TCMP has also been documented to occur in patients with hypothyroid or subclinical hypothyroid states. 60, 80 In a retrospective study, Aggarwal et al found an association of TCMP with thyroid disorders and reported 35% of the patients to be hypothyroid, with the majority of them being on thyroid replacement and 11.36% being in a hyperthyroid state. hypothyroidism, resulting in an imbalance of vagal and sympathetic modulation (Figure 2) . [81] [82] [83] Moreover, the hypothyroid state is known to increase the risk of atherosclerosis and cardiovascular events, increase peripheral resistance, and reduce ventricular function. 74 Proper interpretation of thyroid function testing in the context of the clinical picture is important because patients with Graves disease can present as hyperthyroid or hypothyroid at different times, depending on the ratio of stimulating and blocking thyroid antibodies, commonly described as the "thyroid yo-yo." 84, 85 Also, it should be noted that not all patients with Graves disease actually have thyroid antibodies. Moreover, thyroid tracer uptake may be suppressed in patients on treatment, although increased uptake is expected in Graves disease. 86 Larger studies are needed to better understand the potential association between thyroid disorders and TCMP. In the interim, physicians should be aware of this potential relationship and consider ordering appropriate thyroid function testing in the relevant clinical setting to facilitate prompt diagnosis and treatment.
Adrenal Insufficiency and TCMP
Adrenal insufficiency is a life-threatening entity caused by insufficient glucocorticoid production 87 and is described as primary, secondary, or tertiary, depending on the cause. Primary adrenal insufficiency results from adrenal cortex diseases such as autoimmune disease, infections, hemorrhage, or rarely, malignancy. Central adrenal insufficiency, including secondary and tertiary adrenal insufficiency, is caused by disorders of the hypothalamic-pituitary axis. Presenting symptoms of adrenal insufficiency are often nonspecific, resulting in delayed diagnosis and treatment. Adrenal insufficiency has been associated with changes in cardiac and vascular function, with patients presenting with volume depletion, electrolyte disturbances, diastolic hypotension, decreased stroke volume, and peripheral vascular resistance, cardiac failure, and cardiac atrophy. Impaired hemodynamics with volume contraction and low cardiac output are common in Addisonian crisis, and recovery of normal cardiovascular status is rapidly achieved with prompt fluid resuscitation and steroid therapy. 87 Reversible systolic dysfunction resembling TCMP has been documented in primary and secondary adrenal insufficiency, [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] although the pathophysiologic mechanism remains unknown. There have been conflicting reports in that while in some patients cardiac dysfunction resolved on steroid replacement, in others it worsened. Glucocorticoids play an important role in myocardial contractility by maintaining calcium transport across the cardiac sarcoplasmic reticulum and modulating the vascular response to b-agonists and maintaining cardiac inotropy. [99] [100] [101] [102] [103] [104] In primary adrenal insufficiency, as found in animal experimental models, there is uncoupling of the excitationcontraction pathway resulting in myocardial injury (Figure 2) . 100 Studies in animals have suggested a toxic effect of catecholamines on the myocardium in the absence of glucocorticoids, when adrenalectomized animals were exposed to stress. 101 However, exposure of cortisone-starved myocardium to steroid replacement results in greater sensitivity to the adrenergic system, exaggerating catecholamine-induced cardiac dysfunction, and resulting renal maladaptation leading to excessive water and sodium retention as well as a direct toxic effect of steroids on chronically steroid-deprived tissues. 102, 103 It is unknown whether underlying ischemic, valvular, and hypertensive heart disease in the elderly population is a predisposing factor because the cases describing worsening cardiac function after replacement therapy did not have underlying cardiac disease. Internists, cardiologists, intensivists, and endocrinologists should be aware of this complex association between adrenal insufficiency and cardiac dysfunction, which can often worsen on steroid replacement therapy. It is difficult to estimate the prevalence of TCMP in patients with adrenal disorders, because current information is based on case reports. Details of the 12 cases reporting such an association are summarized in Table 2 .
Diabetes Mellitus and TCMP
Diabetes mellitus with autonomic neuropathy has been associated with a functional deficit in noradrenergic neurons within the hypothalamus and sluggish adrenal epinephrine output, resulting in a low catecholamine state. [105] [106] [107] Clinical and animal studies have documented decreased norepinephrine release from local cardiac sympathetic nerves in longstanding diabetes mellitus even with subtle neuropathy. This has been thought to have a protective effect against TCMP via cardiac and splanchnic sympathetic output impairment. However, the association of TCMP in diabetes mellitus remains debatable. Madias et al described a low prevalence of diabetes mellitus in TCMP in a meta-analysis after analyzing the global literature on TCMP from 2001 to 2014. 108 Another retrospective study by Yayehd et al reported an 11.5% prevalence of diabetes mellitus in a cohort of 117 French patients with TCMP. 109 A report based on 2 Spanish cohorts with 328 patients reported the prevalence of diabetes mellitus to be 13.1%. 110 These studies have suggested that diabetes mellitus may exert a protective effect against catecholamine-driven cardiac dysfunction. However, these studies were retrospective and primarily hypothesis-generating with limited clinical details regarding the duration of diabetes mellitus, the degree of glycemic control, and validation of autonomic neuropathy by clinical testing. In fact, most of the reported literature regarding an association between diabetes mellitus and TCMP does not provide detailed information such as duration of diabetes mellitus, whether it was controlled or uncontrolled, the presence or absence of complications, and the type of diabetes mellitus. The lack of such details can potentially lead to misrepresentation of an association of diabetes mellitus with reversible cardiomyopathy. Generalizability of the reported findings is further limited in that the overall prevalence of diabetes mellitus in Europe is much lower as compared with the rest of the world. 111 However, Templin et al reported a 14.2% prevalence of diabetes mellitus in patients with TCMP enrolled in the International Takotsubo Registry across 9 countries, though on detailed subgroup analysis the prevalence was reduced to 12.8%. 112 This low prevalence was significant as compared with a higher prevalence of diabetes mellitus in the general population. Bill et al 113 have reported a higher prevalence of diabetes mellitus in TCMP (22.8%) in their cohort as compared with 16.8% reported in a meta-analysis. This may have been related to a higher overall prevalence of diabetes mellitus in their cohort, but paradoxically the diabetic patients with TCMP had better short-term and long-term outcomes. According to the pathophysiological link between diabetes mellitus and TCMP, longstanding poorly controlled diabetic patients who are exposed to overwhelming stress can develop a reversible cardiomyopathy after counteracting the postulated diabetic TCMP "protective" effect. However, it is difficult to say whether mild glucose impairment exerts the same cardioprotective effect. Diabetes mellitus has been reported to be an independent predictor of mortality in patients with TCMP in 1 study. 114 TCMP has also been documented in association with diabetic ketoacidosis, hyperglycemic hyperosmolar states, and poorly controlled diabetes mellitus in case reports. [115] [116] [117] Whether stress related to hyperglycemia can be the initial trigger remains unclear. Various explanations postulated include hyperglycemia-induced coronary microvascular dysfunction along with inflammatory and oxidative stress-induced cellular dysfunction. Still, many questions remain unanswered and require prospective studies to validate the clinical association.
Hypoglycemia and TCMP
There are a few case reports suggesting hypoglycemia as a trigger for TCMP. [118] [119] [120] Most of the cases with hypoglycemia occurred in association with anorexia nervosa or adrenal insufficiency. In others, no cause could be identified. Anorexia nervosa is a complicated entity to assess as regards hypoglycemia, given that it causes several metabolic and electrolyte disturbances and will not be covered further here. [121] [122] [123] associated with autoimmune polyendocrine syndrome, results in impaired cardiac contractility though only 1 patient presented with severe hyponatremia. Both cases presented with undertreated hypothyroidism, which could itself result in an increased rate of production and prolonged clearance of norepinephrine. Consistent with the literature showing that catecholamine levels are not always elevated in TCMP, in one of these reports catecholamine levels were found to be normal. The 2 cases are summarized in Table 4 .
Syndrome of Inappropriate Antidiuretic Hormone Secretion and TCMP
Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a form of euvolemic, hypo-osmolar hyponatremia, which is characterized by a negative free water clearance with high urine osmolality and low plasma osmolality in the absence of renal, adrenal, and thyroid insufficiency. 131 The causes of SIADH can include malignancy (small-cell lung cancer, lymphoma), central nervous system-related causes (infections, mass, trauma, bleed), iatrogenic (psychoactive drugs, chemotherapy), pulmonary disorders, and, rarely, genetic causes. The clinical presentation and morbidity and mortality associated with SIADH are related to severity and rapidity of onset as well as duration of hyponatremia. Clinical manifestations of hyponatremia are usually limited to the central nervous system and occur typically at sodium levels <125 mEq/L. Cardiac manifestations in hyponatremia are not common but recently TCMP has been described in patients with severe hyponatremia in the setting of subarachnoid hemorrhage, head trauma, adrenal insufficiency, thyroid dysfunction, and SIADH. [131] [132] [133] [134] [135] [136] [137] [138] [139] Hyponatremia has been shown to exist in 32.1% of cases of TCMP. 140 However, many of the cases demonstrating a relationship between hyponatremia and TCMP had confounding factors present such as hypothyroidism, adrenal insufficiency, and seizures. Table 5 summarizes all the cases with confirmed diagnoses of SIADH associated with TCMP. The mechanism of transient cardiac dysfunction in the setting of hyponatremia remains unknown. In cases associated with seizures, catecholamine-mediated processes may be explanatory but some cases have reported elevated dopamine and norepinephrine levels, possibly triggering TCMP by a mechanism other than a catecholaminemediated one. 136 Animal models have suggested a role of intracellular calcium overload caused by impaired function of the myocyte membrane sodium-calcium pumps in the setting of hyponatremia, resulting in myocardial dysfunction and arrythmogenesis. 141 Others have postulated a role of intracellular fluid shifts resulting in cellular edema. This is further supported by the finding of myocardial edema seen on cardiac imaging in patients with TCMP. 136, 140 The reported threshold of serum sodium levels at which TCMP develops has varied in different cases. Kawano et al 136 reported the occurrence of TCMP in 1 patient at a serum sodium concentration of 105 mEq/L, although no cardiac dysfunction occurred at serum sodium levels of 110 mEq/L in the reported prior hospital admission. An important variable to consider is the occurrence of seizures that may vary with the sodium concentration. Not all cases reporting TCMP with hyponatremia actually had a seizure episode. Therefore, though the severity of hyponatremia may predispose to reversible cardiac dysfunction, whether factors other than hyponatremia alone contribute to the cause in cases of SIADH is yet to be answered.
Conclusion
Although a number of case reports have described an association of TCMP with endocrine disorders, at this time it is difficult to provide a reliable estimate of how frequently these associations occur. Furthermore, the causal link between endocrine disorders and TCMP is still debatable and requires further research and a larger database. The development of TCMP registries across different countries could serve as a resource to help provide answers to these questions. Nevertheless, it seems imperative that clinicians be aware of such potential associations, given that identification of an endocrine disorder in a patient with TCMP may offer a potentially great therapeutic opportunity. Therefore, we suggest that as this association undergoes further study, clinicians evaluating patients with TCMP would be well advised to have a low threshold to screen such patients for endocrine dysfunction.
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